Biggest News Aggregation in the World
📰 Scott Struthers News

Page 4 - Scott Struthers News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Scott Struthers. Real-time updates on events, politics, business and more.

Evercore ISI Increases Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $48.00

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) had its price target upped by Evercore ISI from $41.00 to $48.00 in a research report issued to clients and investors on Monday, FlyOnTheWall reports. Evercore ISI’s target price would indicate a potential upside of 200.56% from the company’s previous close. A number of other research firms also […]
Zurcher Kantonalbank Zurich Cantonalbank Robertw Baird Richard Scott Struthers Marc Wilson Insider Activity At Crinetics Pharmaceuticals Hedge Funds Weigh In On Crinetics Pharmaceuticals

Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $40.00 price objective on the stock. A number of other research firms have also recently issued reports on CRNX. Robert W. Baird reduced their […]
Richard Scott Struthers Coelho Rogerio Vivaldi Zurcher Kantonalbank Zurich Cantonalbank Robertw Baird Securities Exchange Commission News Ratings For Crinetics Pharmaceuticals Daily

Crinetics Pharmaceuticals (NASDAQ:CRNX) Given New $33.00 Price Target at HC Wainwright

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target cut by HC Wainwright from $35.00 to $33.00 in a research note released on Wednesday morning, MarketBeat Ratings reports. The firm currently has a buy rating on the stock. A number of other equities analysts also recently commented on CRNX. JMP Securities boosted their price […]
New Zealand General New Zealand Richard Scott Struthers Coelho Rogerio Vivaldi Piper Sandler Crinetics Pharmaceuticals Stock

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Bourgeon Capital Management LLC Grows Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Bourgeon Capital Management LLC raised its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) by 56.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,150 shares of the company’s stock after buying an additional 1,500 shares during the quarter. […]
Piper Sandler Dana Pizzuti Richard Scott Struthers Robertw Baird Crinetics Pharmaceuticals Inc Exchange Commission

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $1,040,500.00 in Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) CEO Richard Scott Struthers sold 50,000 shares of the business’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $20.81, for a total transaction of $1,040,500.00. Following the sale, the chief executive officer now owns 680,805 shares in the company, […]
Zurcher Kantonalbank Zurich Cantonalbank Robertw Baird Richard Scott Struthers Piper Sandler Quarter For Crinetics Pharmaceuticals Tower Research Capital

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.5% After Insider Selling

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating)’s share price traded down 5.5% during trading on Thursday following insider selling activity. The company traded as low as $18.58 and last traded at $18.62. 204,711 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 444,003 shares. The stock had previously […]
Piper Sandler Richard Scott Struthers Zurcher Kantonalbank Zurich Cantonalbank Marc Wilson Robertw Baird Crinetics Pharmaceuticals

Top in endocrinology: Testosterone replacement; lower long COVID risk in metformin users

In the TRAVERSE trial, men with hypogonadism at high risk for CVD who received testosterone had a similar risk for major adverse cardiovascular events compared with those who received placebo. A. Michael Lincoff, MD, vice chair for research, cardiovascular medicine and professor of medicine at Cleveland Clinic, said during a presentation at ENDO 2023 that the findings “should
R Scott Struthers Pa Michael Lincoff Healio Coverage Michael Lincoff Cleveland Clinic Scott Struthers
Source: healio.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science